EC Number   |
Application |
Reference |
|---|
    1.14.14.23 | analysis |
development of a straightforward dual-reporter bioluminescent assay to simultaneously monitor isoform CYP7A1 transcriptional regulation and cell viability in Chlamydia pneumoniae and human cytomegalovirus infected human hepatoblastoma Hep-G2 cells |
723941 |
| 1.14.14.23 | medicine |
association of CYP7A1 gene polymorphisms with the risk of gallbladder cancer. This polymorphism plays a significant role in the pathogenesis of gallbladder cancer which is causatively related to depressed bile acid production. The proposed tumorigenic mechanism for gallbladder cancer is independent of gallstone pathway and appears to be mediated by increase in concentration and accumulation of toxic substances in gallbladder, generated in liver as a consequence of lipid peroxidation and other catabolic reactions |
689029 |
| 1.14.14.23 | medicine |
Chlamydia pneumoniae and human cytomegalovirus infections significantly decrease isoform CYP7A1 promoter activity in a dose-dependent manner, with maximal inhibitions of 33% and 32%, respectively |
723941 |
| 1.14.14.23 | medicine |
CYP7A1 overexpression in transgenic mice leads to marked activation of the steroid response element-binding protein 2-regulated cholesterol metabolic network and absence of bile acid repression of lipogenic gene expression in livers. Cyp7a1-tg mice show significantly elevated hepatic cholesterol synthesis rates, but reduced hepatic fatty acid synthesis rates, which is accompanied by increased 14C-glucose-derived acetyl-coenzyme A incorporation into sterols for fecal excret |
725114 |
| 1.14.14.23 | medicine |
in inborn error of metabolism known as Smith-Lemli-Opitz syndrome, 7-oxocholesterol levels may also be elevated in tissue and fluids as a result of CYP7A1 oxidation of 7-dehydrocholesterol |
725442 |
| 1.14.14.23 | medicine |
manipulation of hormone signaling pathways can provide a strategy to enhance Cyp7a1 activity in human patients |
736800 |
| 1.14.14.23 | medicine |
polymorphisms/mutations described so far at the CYP7A1 promoter do not impair enzyme activity and most likely do not contribute directly to hypercholesterolemia and/or increased cardiovascular risk |
689381 |
| 1.14.14.23 | medicine |
upregulation of CYP7A1 mRNA in hypercholesterolemic rats treated with extracts from steamed and dried roots of Panax ginseng C.A. Meyer. Treatment leads to decreased ratios of low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol. In-vitro studies also show the upregulation of CYP7A1 mRNA and protein levels by the addition of ginsenosides Ro, Rg3, Re, Rg1, and Rg2 to rat primary hepatocytes |
725766 |
